RPRX Royalty Pharma plc
Royalty Pharma plc (RPRX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $6.4M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Hite Christopher | EVP & Chairman, Partnering | Sell 10b5-1 | 100,000 | $59.97 | $6.0M | 370,401 −21.3% of holding | |
| Coyne Terrance P. 2 fills | EVP & CFO | Sell 10b5-1 | 11,002 | $58.68 | $645.6K | 1,772 −86.1% of holding | |
| Urist Marshall | EVP, Research & Investments | Sell 10b5-1 | 9,099 | $55.88 | $508.5K | None left | |
| Hite Christopher 4 fills | EVP & Chairman, Partnering | Sell 10b5-1 | 130,000 | $56.50 | $7.3M | 461,953 −22% of holding | |
| Urist Marshall | EVP, Research & Investments | Sell 10b5-1 | 9,098 | $55.18 | $502.1K | 9,099 −50% of holding | |
| Hite Christopher 2 fills | EVP & Chairman, Partnering | Sell 10b5-1 | 150,000 | $54.40 | $8.2M | 676,991 −18.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.